Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TWi Pharma Granted US Orphan Drug Designation for Lead Molecule

publication date: Oct 21, 2014
TWi Pharma of Taiwan has been granted Orphan Drug designation in the US by the FDA for the use of AC-201 to treat a rare genetic skin disease, epidermolysis bullosa. EB, which affects one person out of every 50,000 births, results in extremely fragile skin that blisters and tears from friction or trauma. In June 2014, TWi established a China connection by acquiring a majority stake in Visum Pharma, located in Hainan. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital